Confo Therapeutics’ technology stabilizes functional conformations of G protein-coupled receptors to uncover a wide range of previously inaccessible drug targets.
Confo Therapeutics, a spin-off of the Vrije Universiteit Brussel and VIB, is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations of these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
Animab develops antibodies to tackle gastrointestinal pathogens in livestock.
Spica Therapeutics is pioneering Macrophage-Subset targeted therapies
Weavely helps companies test and validate digital products before launch.
